Celldex Therapeutics Inc(CLDX) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, which is being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in metastatic solid tumors and B cell lymphomas; CDX-3379, a monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-0159, a Phase I monoclonal antibody that binds the KIT receptor and inhibits its activity; and CDX-527, a bispecific antibody that uses anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway. The company also holds exclusive rights to CDX-301 and CD40 ligand, which are immune modulating molecules that increase the numbers and activity of immune cells that control immune responses. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton; Amgen Inc.; Yale University; and MedImmune, LLC. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Current Price

$27.31

RSI

39.321

Beta:

2.940981

November 05, 2020
3.8M
-12M

23.993 %
90.004 %
-24.630 %
-4.204 %

$3,562,000
$8,318,000
$12,743,000
$6,786,000
$5,480,000
$3,586,000
-133.520 %
-53.198 %
87.784 %
23.832 %
52.817 %

$-50,878,000
$-151,949,000
$-117,313,000
$-132,916,000
$-129,541,000
$-118,080,000
198.654 %
-22.794 %
13.300 %
-2.539 %
-8.847 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.